BioNTech SE (BNTX) Receivables - Other (2018 - 2019)
BioNTech SE (BNTX) posted Receivables - Other of $6.5 million for Q4 2019, down 26.56% on a QoQ basis from $8.8 million in Q3 2019, and up 142.11% year-over-year from $2.7 million in Q4 2018.
BioNTech SE (BNTX) has 2 years of Receivables - Other data on file, last reported at $6.5 million in Q4 2019.
- In Q4 2019, Receivables - Other rose 142.11% year-over-year to $6.5 million; the TTM figure through Dec 2019 stood at $6.5 million (up 142.11% YoY), while the FY2019 annual figure was $6.5 million, up 133.93% from the prior year.
- Receivables - Other eased to $6.5 million in Q4 2019, from $8.8 million in the prior quarter.
- Across five years, Receivables - Other topped out at $8.8 million in Q3 2019 and bottomed at $2.7 million in Q4 2018.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | BioNTech SE | 27.66 Bn | 7.53 Bn | 668.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 6.49 Mn |
| Dec 31, 2019 | 6.49 Mn |
| Sep 30, 2019 | 8.84 Mn |
| Sep 30, 2019 | 8.84 Mn |
| Dec 31, 2018 | 2.68 Mn |
| Dec 31, 2018 | 2.68 Mn |